Two other pharmaceutical companies have their own oral GLP-1 drugs in the works: Orforglipron: Developed by Eli Lilly, its in Phase 3 clinical trials for treating type 2 diabetes and obesity, with an expected September 2025 completion
Understanding the Injection Process Tirzepatide is administered as a subcutaneous injection (just under the skin) once a week
Tirzepatide mimics glucagon-like peptide-1, stimulating insulin release in response to meals, suppressing glucagon, and slowing gastric emptying
Neuropathic pain and diabetic neuropathy We identified 19 animal studies evaluating the role of GLP-1 in neuropathic pain [31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49]
Mechanism of trypsin-induced endothelium-dependent vasorelaxation in the porcine coronary artery
What does PlexusDx's Precision Peptide Genetic Test reveal about my hypoglycemia risk